Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Assessment of Enhanced Levodopa Effects in Conjunction with Acute of Administration of Various Endocannabinoid Modulating Compounds, and Chronically to Assess Effects on Levodopa Induced Dyskinesia (LID) in a Pharmacologically induced Dopamine Deficient-Dopamine Transporter Knockout Parkinson's Model
EF 2023-24
Résumé
Parkinson's disease is a neurological disorder that results in resting tremor, postural instability, difficulty coordinating movement and difficulty walking. Dopamine, an important neurotransmitter involved in motor control, is implicated in Parkinson's disease. As dopaminergic neurons die, symptoms of Parkinson's emerge. The main pharmaceutical treatment for Parkinson's is L-DOPA, the precursor of dopamine. Unfortunately, prolonged usage and high doses of L-DOPA are associated with a major side effect known as L-DOPA Induced Dyskinesia. Treatments that would enhance L-DOPA and reduce the dose required for therapeutic effect are highly desired as they can potentially delay the development of L-DOPA Induced Dyskinesia. The endocannabinoid system is known to modulate dopamine transmission, including L-DOPA responses. Studies from our lab have shown that the inhibition of MAGL (an important degradation enzyme in endocannabinoid system) increases motor activity in mice treated with L-DOPA, which would also be beneficial for Parkinson's Disease (a disease presenting with reduced motor activity). In this project, we aim to refine our studies and test the effects of several drug compounds that act on the endocannabinoid system and see if these compounds can increase L-DOPA responses. We plan to study a variety of MAGL inhibitors and other endocannabinoid modulating compounds. Results from our studies can be of major interest to Parkinson's patients. With the legalization of cannabis in Canada, there is a great interest in cannabinoids from the general public and our research seeks to understand how endocannabinoid-based therapies can be beneficial for Parkinson's disease. Our hypothesis is that drug treatments that would increase L-DOPA efficacy or duration would be beneficial for therapeutic intervention in Parkinson's, and could reduce or delay the development of L-DOPA Induced Dyskinesia, which is a major side effect associate with L-DOPA use in Parkinson's patients.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
496573
Name
Zovko Lola E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Assessment of Enhanced Levodopa Effects in Conjunction with Acute of Administration of Various Endocannabinoid Modulating Compounds, and Chronically to Assess Effects on Levodopa Induced Dyskinesia (LID) in a Pharmacologically induced Dopamine Deficient-Dopamine Transporter Knockout Parkinson's Model
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Animal Behaviour; Behavioural Pharmacology; Dopamine Deficient Mouse Model; Dopaminergic System; Endocannabinoid System; Levodopa Induced Dyskinesia; Neuropharmacology; Novel Drug Applications; Parkinson'S Disease; Pre-Clinical Parkinson'S Model
Abstract
Parkinson's disease is a neurological disorder that results in resting tremor, postural instability, difficulty coordinating movement and difficulty walking. Dopamine, an important neurotransmitter involved in motor control, is implicated in Parkinson's disease. As dopaminergic neurons die, symptoms of Parkinson's emerge. The main pharmaceutical treatment for Parkinson's is L-DOPA, the precursor of dopamine. Unfortunately, prolonged usage and high doses of L-DOPA are associated with a major side effect known as L-DOPA Induced Dyskinesia. Treatments that would enhance L-DOPA and reduce the dose required for therapeutic effect are highly desired as they can potentially delay the development of L-DOPA Induced Dyskinesia. The endocannabinoid system is known to modulate dopamine transmission, including L-DOPA responses. Studies from our lab have shown that the inhibition of MAGL (an important degradation enzyme in endocannabinoid system) increases motor activity in mice treated with L-DOPA, which would also be beneficial for Parkinson's Disease (a disease presenting with reduced motor activity). In this project, we aim to refine our studies and test the effects of several drug compounds that act on the endocannabinoid system and see if these compounds can increase L-DOPA responses. We plan to study a variety of MAGL inhibitors and other endocannabinoid modulating compounds. Results from our studies can be of major interest to Parkinson's patients. With the legalization of cannabis in Canada, there is a great interest in cannabinoids from the general public and our research seeks to understand how endocannabinoid-based therapies can be beneficial for Parkinson's disease. Our hypothesis is that drug treatments that would increase L-DOPA efficacy or duration would be beneficial for therapeutic intervention in Parkinson's, and could reduce or delay the development of L-DOPA Induced Dyskinesia, which is a major side effect associate with L-DOPA use in Parkinson's patients.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Zovko, Lola E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~